The observed reduction in CXCR4+/CD105+ vessels following CXCR4 inhibition in the MOC2 model supports the therapeutic potential of targeting CXCR4 to disrupt tumor vasculature and limit tumor viability. Here, CXCR4 is linked to neoplasm.